↓ Skip to main content

Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial

Overview of attention for article published in The Journal of Headache and Pain, April 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#42 of 1,537)
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
13 news outlets
blogs
1 blog
twitter
23 X users
facebook
3 Facebook pages
googleplus
1 Google+ user
video
2 YouTube creators

Citations

dimensions_citation
125 Dimensions

Readers on

mendeley
248 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial
Published in
The Journal of Headache and Pain, April 2015
DOI 10.1186/s10194-015-0516-6
Pubmed ID
Authors

Charly Gaul, Hans-Christoph Diener, Ulrich Danesch, on behalf of the Migravent® Study Group

Abstract

Non-medical, non-pharmacological and pharmacological treatments are recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled, multicenter trial was to evaluate the efficacy of a proprietary nutritional supplement containing a fixed combination of magnesium, riboflavin and Q10 as prophylactic treatment for migraine. 130 adult migraineurs (age 18 - 65 years) with ≥ three migraine attacks per month were randomized into two treatment groups: dietary supplementation or placebo in a double-blind fashion. The treatment period was 3 months following a 4 week baseline period without prophylactic treatment. Patients were assessed before randomization and at the end of the 3-month-treatment-phase for days with migraine, migraine pain, burden of disease (HIT-6) and subjective evaluation of efficacy. Migraine days per month declined from 6.2 days during the baseline period to 4.4 days at the end of the treatment with the supplement and from 6.2.days to 5.2 days in the placebo group (p = 0.23 compared to placebo). The intensity of migraine pain was significantly reduced in the supplement group compared to placebo (p = 0.03). The sum score of the HIT-6 questionnaire was reduced by 4.8 points from 61.9 to 57.1 compared to 2 points in the placebo-group (p = 0.01). The evaluation of efficacy by the patient was better in the supplementation group compared to placebo (p = 0.01). Treatment with a proprietary supplement containing magnesium, riboflavin and Q10 (Migravent® in Germany, Dolovent® in USA) had an impact on migraine frequency which showed a trend towards statistical significance. Migraine symptoms and burden of disease, however, were statistically significantly reduced compared to placebo in patients with migraine attacks.

X Demographics

X Demographics

The data shown below were collected from the profiles of 23 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 248 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 <1%
Brazil 1 <1%
Colombia 1 <1%
United Kingdom 1 <1%
Japan 1 <1%
Unknown 242 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 44 18%
Student > Master 33 13%
Other 26 10%
Student > Doctoral Student 22 9%
Researcher 18 7%
Other 38 15%
Unknown 67 27%
Readers by discipline Count As %
Medicine and Dentistry 79 32%
Nursing and Health Professions 35 14%
Agricultural and Biological Sciences 17 7%
Biochemistry, Genetics and Molecular Biology 11 4%
Pharmacology, Toxicology and Pharmaceutical Science 9 4%
Other 22 9%
Unknown 75 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 128. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 February 2024.
All research outputs
#326,184
of 25,455,127 outputs
Outputs from The Journal of Headache and Pain
#42
of 1,537 outputs
Outputs of similar age
#3,689
of 279,552 outputs
Outputs of similar age from The Journal of Headache and Pain
#2
of 23 outputs
Altmetric has tracked 25,455,127 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,537 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,552 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.